Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation

Abstract
OVER THE LAST decade the management of patients with atrial fibrillation has become a subject of increasing interest. New antiarrhythmic agents have become available,1-8 large clinical trials9-13 have demonstrated the efficacy of antithrombotic therapy, and there has been increasing awareness that agents used to maintain sinus rhythm may have serious or fatal adverse effects.14-16

This publication has 2 references indexed in Scilit: